Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic practice setting. Methods: All HCV monoinfected and HCV/HIV coinfected patients treated with DAAs between January 2014 and October 2017 in community clinic settings were retrospectively analyzed. Pretreatment baseline patient characteristics, treatment efficacy, factors affecting sustained virologic response at 12 weeks (SVR12) after treatment, and adverse reactions were compared between the groups. Results: A total of 327 patients were included in the study, of which 253 were HCV monoinfected, and 74 were HCV/HIV coinfected. There was a statistically significant difference observed in SVR12 when comparing HCV monoinfection and HCV/HIV coinfection (94% and 84%, respectively, p=0.005). However, there were no significant factors identified as a predictor of a reduced response. The most common adverse effect was fatigue (27%). No significant drug interaction was observed between DAA and antiretroviral therapy. None of the patients discontinued the treatment due to adverse events. Conclusions: In a real-world setting, DAA regimens have lower SVR12 in HCV/HIV coinfection than in HCV monoinfection. Further studies involving a higher number of HCV/HIV coinfected patients are needed to identify real predictors of a reduced response.
Abstract
Background/Aims: Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic practice setting. Methods: All HCV monoinfected and HCV/HIV coinfected patients treated with DAAs between January 2014 and October 2017 in community clinic settings were retrospectively analyzed. Pretreatment baseline patient characteristics, treatment efficacy, factors affecting sustained virologic response at 12 weeks (SVR12) after treatment, and adverse reactions were compared between the groups. Results: A total of 327 patients were included in the study, of which 253 were HCV monoinfected, and 74 were HCV/HIV coinfected. There was a statistically significant difference observed in SVR12 when comparing HCV monoinfection and HCV/HIV coinfection (94% and 84%, respectively, p=0.005). However, there were no significant factors identified as a predictor of a reduced response. The most common adverse effect was fatigue (27%). No significant drug interaction was observed between DAA and antiretroviral therapy. None of the patients discontinued the treatment due to adverse events. Conclusions: In a real-world setting, DAA regimens have lower SVR12 in HCV/HIV coinfection than in HCV monoinfection. Further studies involving a higher number of HCV/HIV coinfected patients are needed to identify real predictors of a reduced response.
참고문헌 (39)
- Balogun MA, "The prevalence of hepatitis C in England and Wales", J Infect, 45, pp.219~226 (2002)
- Mocroft A, "AIDS across Europe, 1994-98: the EuroSIDA study", Lancet, 356, pp.291~296 (2000)
- Kirk GD, "HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study", Ann Intern Med, 158, pp.658~666 (2013)
- Goedert JJ, "End-stage liver disease in persons with hemophilia and transfusion-associated infections", Blood, 100, pp.1584~1589 (2002)
- Vogel M, "Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals", Clin Infect Dis, 54, pp.556~559 (2012)
- Soriano V, "Regression of liver fibrosis in hepatitis C virus", HIV-coinfected patients after treatment with pegylated interferon plus ribavirin, 2006, pp.20, 2225~2227
- Hepatitis C Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, "Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus", HIV-positive patients, 2017, pp.31, 661~668
- Berenguer J, "Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis", J Acquir Immune Defic Syndr, 66, pp.280~287 (2014)
- Labarga P, "Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients", J Infect Dis, 196, pp.670~676 (2007)
- Martin TC, "Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM", AIDS, 27, pp.2551~2557 (2013)
- Hulskotte EG, "Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir", Clin Infect Dis, 56, pp.718~726 (2013)
- Torriani FJ, "Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients", N Engl J Med, 351, pp.438~450 (2004)
- Sulkowski MS, "Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection", JAMA, 312, pp.353~361 (2014)
- Osinusi A, "Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection", JAMA, 313, pp.1232~1239 (2015)
- Saeed S, "How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV", HCV in the real world, 2016, pp.62, 919~926
- Bhattacharya D, "Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus", hepatitis C virus genotype 1-coinfected patients treated in routine practice, 2017, pp.64, 1711~1720
- Khatri A, "Evaluation of drug-drug interactions between hepatitis C antiviral agents ombitasvir, paritaprevir", ritonavir, and dasabuvir and HIV-1 protease inhibitors, 2016, pp.62, 972~979
- Wyles D, "TURQUOISE-I Part 1b: ombitasvir", paritaprevir, J Infect Dis, pp.2017, 215[DOI]
- European Association for Study of Liver, "EASL recommendations on treatment of hepatitis C 2015", J Hepatol, 63, pp.199~236 (2015)
- AASLD, "IDSA HCV Guidance Panel", Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, 2015, pp.62, 932~954
- ordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
- Milazzo L, "Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV", HIV-coinfected patients: real-life safety and efficacy, 2017, pp.18, 284~291
- Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", N Engl J Med, 370, pp.1889~1898 (2014)
- Afdhal N, "Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection", N Engl J Med, 370, pp.1483~1493 (2014)
- Ferenci P, "ABT-450", r-ombitasvir and dasabuvir with or without ribavirin for HCV, 2014, pp.370, 1983~1992
- Lawitz E, "Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study", Lancet, 384, pp.1756~1765 (2014)
- Rivero-Juarez A, "Baseline risk factors for relapse in HIV", HCV co-infected patients treated with PEG-IFN, Infection, pp.2013, 41[DOI]
- Rallón NI, "Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV", hepatitis C virus-coinfected patients, 2010, pp.24, F23~F29
- Bruno G, "HCV mono-infected and HIV", HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ, 2017, pp.62, 64~71
- Werner CR, "Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12", World J Gastroenterol, 22, pp.8050~8059 (2016)
- Neukam K, "HIVcoinfected patients respond worse to direct-acting antiviralbased therapy against chronic hepatitis C in real life than HCVmonoinfected individuals: a prospective cohort study", HIV Clin Trials, 18, pp.126~134 (2017)
- Naggie S, "Ledipasvir and sofosbuvir for HCV inpatients coinfected with HIV-1", N Engl J Med, 373, pp.705~713 (2015)
- Lawitz E, "Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatmentnaive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial", Lancet, 383, pp.515~523 (2014)
- Jansen JW, "Identification of predictors for treatment failure in hepatitis C virus patients treated with ledipasvir and sofosbuvir", Ann Pharmacother, 51, pp.543~547 (2017)
- Cavalcante LN, "Predictive factors associated with hepatitis C antiviral therapy response", World J Hepatol, 7, pp.1617~1631 (2015)
- Lawitz E, "Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2)", Hepatology, 64, pp.360~369 (2016)
- Marot A, "Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding", Liver Int, 37(707), pp.707~716 (2017)
- Leroy V, "Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)", Hepatology, 63, pp.1430~1441 (2016)